BRPI0308256A2 - agentes para a terapia preventiva após ataque de apoplexia agudo - Google Patents

agentes para a terapia preventiva após ataque de apoplexia agudo

Info

Publication number
BRPI0308256A2
BRPI0308256A2 BRPI0308256A BR0308256A BRPI0308256A2 BR PI0308256 A2 BRPI0308256 A2 BR PI0308256A2 BR PI0308256 A BRPI0308256 A BR PI0308256A BR 0308256 A BR0308256 A BR 0308256A BR PI0308256 A2 BRPI0308256 A2 BR PI0308256A2
Authority
BR
Brazil
Prior art keywords
agents
acute stroke
preventive therapy
stroke attack
attack
Prior art date
Application number
BRPI0308256A
Other languages
English (en)
Inventor
Andreas Meisel
Christian Meisel
Elke Halle
Hans Dieter Volk
Konstantin Prass
Ulrich Dirnagl
Original Assignee
Universitätsklinikum Charité Der Humboldt Universität Zu Berlin Technologietransferstelle
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitätsklinikum Charité Der Humboldt Universität Zu Berlin Technologietransferstelle filed Critical Universitätsklinikum Charité Der Humboldt Universität Zu Berlin Technologietransferstelle
Publication of BRPI0308256A2 publication Critical patent/BRPI0308256A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0308256A 2002-03-05 2003-03-05 agentes para a terapia preventiva após ataque de apoplexia agudo BRPI0308256A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10210536 2002-03-05
DE10218328A DE10218328A1 (de) 2002-03-05 2002-04-24 Mittel zur präventiven Therapie nach akutem Schlaganfall
PCT/EP2003/002246 WO2003074057A1 (de) 2002-03-05 2003-03-05 Antiinfektiva und/oder immunnodulatoren zur präventiven therapie nach akutem schlaganfall

Publications (1)

Publication Number Publication Date
BRPI0308256A2 true BRPI0308256A2 (pt) 2016-06-21

Family

ID=27789739

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0308256A BRPI0308256A2 (pt) 2002-03-05 2003-03-05 agentes para a terapia preventiva após ataque de apoplexia agudo

Country Status (15)

Country Link
US (1) US8673934B2 (pt)
EP (1) EP1480646B1 (pt)
JP (1) JP2005525361A (pt)
CN (1) CN1652785A (pt)
AT (1) ATE402702T1 (pt)
AU (1) AU2003219016B2 (pt)
BR (1) BRPI0308256A2 (pt)
CA (1) CA2478133A1 (pt)
DE (2) DE10218328A1 (pt)
DK (1) DK1480646T3 (pt)
ES (1) ES2311093T3 (pt)
MX (1) MXPA04008573A (pt)
PT (1) PT1480646E (pt)
RU (1) RU2327454C2 (pt)
WO (1) WO2003074057A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005053679A1 (de) * 2005-06-24 2006-12-28 Bayer Healthcare Ag Therapeutischer Einsatz von Moxifloxacin zur Rekonstruktion von Funktionsstörungen des Immunsystems
DE102007020152A1 (de) 2007-04-26 2008-10-30 Charité - Universitätsmedizin Berlin Mittel zur antiinfektiven Behandlung eines Patienten
US9598488B2 (en) * 2008-02-01 2017-03-21 Albany Medical College Blockage of interferon-gamma for prevention of polymicrobial synergy
RU2571282C1 (ru) * 2014-05-22 2015-12-20 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Способ лечения инсульта
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
SG11202101255UA (en) 2018-08-09 2021-03-30 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
CN110964778B (zh) * 2018-09-29 2024-02-23 南方医科大学珠江医院 肠杆菌科作为缺血性脑卒中生物标志物的用途
EP4574146A1 (en) * 2023-12-18 2025-06-25 Telara Pharma S.L. Dhp-i inhibitors for use as neuroprotectants and in the treatment of neuroinflammatory diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4437868A1 (de) * 1994-10-22 1996-04-25 Boehringer Ingelheim Int Behandlung von HLA-DR-assoziierter Immundefizienz mit Interferon-gamma
CN1194828A (zh) 1998-04-22 1998-10-07 王卫东 具有协同作用的美洛西林和舒巴坦的药物组合物
DE19937116A1 (de) * 1999-08-06 2001-02-08 Bayer Ag Moxifloxacin Kochsalzformulierung
HK1052876B (en) * 1999-12-30 2006-06-16 Intermune, Inc. Gamma-ifn liquid-droplet aerosol and method

Also Published As

Publication number Publication date
WO2003074057A8 (de) 2005-09-29
AU2003219016B2 (en) 2008-10-16
US8673934B2 (en) 2014-03-18
CN1652785A (zh) 2005-08-10
RU2004129591A (ru) 2005-09-20
WO2003074057A1 (de) 2003-09-12
EP1480646A1 (de) 2004-12-01
ES2311093T3 (es) 2009-02-01
DE10218328A1 (de) 2003-09-25
PT1480646E (pt) 2008-11-03
JP2005525361A (ja) 2005-08-25
DK1480646T3 (da) 2008-11-24
AU2003219016A1 (en) 2003-09-16
EP1480646B1 (de) 2008-07-30
US20050234089A1 (en) 2005-10-20
DE50310242D1 (de) 2008-09-11
MXPA04008573A (es) 2005-09-08
CA2478133A1 (en) 2003-09-12
ATE402702T1 (de) 2008-08-15
RU2327454C2 (ru) 2008-06-27

Similar Documents

Publication Publication Date Title
NO20005224L (no) BTK inhibitorer og fremgangsmåter for deres identifikasjon og anvendelse
BRPI0418384A (pt) composições farmacêuticas e métodos referentes à inibição de adesões fibrosas utilizando diversos agentes
UA89220C2 (ru) Способ лечения вич/спида путем приема без пищи или в условиях голодания твердого фармацевтического дозированного состава ингибитора вич-протеазы
CL2007003594A1 (es) Compuestos derivados de heterociclos condensados de nitrogeno, inhibidores de transcriptasa inversa no nucleosidicos; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del sida.
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
PT1648484E (pt) Formulações para o tratamento de distúrbios artríticos
CL2007002346A1 (es) Compuestos no nucleosidicos derivados de fenoxi-fenil sustituidos, inhibidores de la transcriptasa inversa del vih; composicion farmaceutica; y su uso para tratar prevenir una infeccion vih o para tratar el sida o crs.
WO2008042480A3 (en) Epoxide inhibitors of cysteine proteases
BRPI0416812A (pt) métodos e reagentes para o tratamento de desordens inflamatórias
CL2015001086A1 (es) Combinación farmacéutica para el tratamiento y/o quimiosensibilizacion de tumores refractarios a drogas anticancerigenas
CL2007001826A1 (es) Compuestos derivados de 2-(amino-sustituido)-benzotiazol-sulfonamida, inhibidores de proteasa, en particular, inhibidores de proteasa de vih; composicion farmaceutica; y uso para tratar o combatir una infeccion o enfermedad asociada con la infeccion de un retrovirus resistente a multiples farmacos.
BRPI0718469A2 (pt) Uso de um antagonista de interleucina 1 (il-1), método para tratar, inibir, ou melhorar pseudogota, uso de um ou mais agentes terapêuticos, e, produto.
CL2004001004A1 (es) Combinacion farmaceutica que comprende irinotecan y revimid para tratar el mieloma multiple.
BRPI0308256A2 (pt) agentes para a terapia preventiva após ataque de apoplexia agudo
BRPI0411176A (pt) combinação farmacêutica consistindo de modafinil e outra droga
EE200300547A (et) Laiaspektrilised 2-aminobensoksasoolsulfoonamiidid kui HIV proteaasi inhibiitorid, nende kasutamine, farmatseutiline kompositsioon ja meetod retroviiruse replikatsiooni inhibeerimiseks
UY30652A1 (es) N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)piperidin-4-ilideno)metil)benzamida
WO2003065991A3 (en) N-substituted3-hydroxy-4-pyridinones and pharmaceuticals containing thereof
WO2004078180A3 (en) Naaladase inhibitors for treating opioid tolerance
BR0111785A (pt) Composições e métodos para tratamento de candidìase
BRPI0713792A8 (pt) uso de derivados de estilbeno para tratamento e prevenção de infecções por fungos aquáticos
MY139425A (en) Pharmaceutical composition comprising 2,4-dichlorobenzyl alcohol and amylmetacresol
BRPI0416027A (pt) sistema de entrega de drogas para inibidores de bomba de prótons e processo resultante
DK1458391T3 (da) Fremgangsmåde til at behandle bakterielle infektioner ved anvendelse af gemifloxacin eller et salt deraf og et beta-lactamantibiotikum
DK1458390T3 (da) Fremgangsmåde til behandling af bakterielle infektioner ved anvendelse af gemifloxacin eller et salt deraf og et carbapenem antibakterielt middel

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A, 10A, 11A, 12A E 13A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.